SCHEMBL2124362

SCHEMBL2124362

CC(=O)Nc1ccc(-c2nc3c(C#N)c[nH]n3c2Nc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.43
▸ GAA P10253 7/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ BRAF P15056 1/20 0.42
▸ TP53 P04637 2/20 0.42
▸ KDM5A P29375 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126473 0.89 MAPT (0.43) MAPTGAAKDM4EMAPK1TP53
SCHEMBL2123121 0.88 MAPT (0.54) MAPTGAAKDM4EMAPK1TP53
SCHEMBL2123221 0.86 MAPT (0.55) MAPTGAAKDM4EMAPK1TP53
SCHEMBL2123871 0.81 MAPT (0.46) MAPTTP53KDM5APOLB
SCHEMBL2122218 0.81 MAOB (0.44) MAPTGAAKDM4EMAPK1TP53
SCHEMBL2123707 0.80 KDM5A (0.46) MAPTGAATP53KDM5APOLB
SCHEMBL2873341 0.79 TGFBR1 (0.45) MAPTGAAKDM4ETP53POLB
SCHEMBL2124513 0.79 LMNA (0.41) MAPTGAAKDM4EMAPK1TP53
SCHEMBL2126127 0.79 KDM5A (0.48) MAPTTP53KDM5APOLB
SCHEMBL2125488 0.79 KDM5A (0.48) MAPTTP53KDM5APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK MAPT 4045/4885GAA 502/4885KDM4E 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback